Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Ansun, Apeiron, Cytodyn, Eusa, Hutchison China Meditech, I-Mab, Inflarx, Inovio, Kiniksa, Nanocarrier, Novan, Oncoceutics, Sato, Synairgen, Vanda, VBL.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Applied, Celularity, Cytodyn, Eisai, Faron, Gracell, I-Mab, Mallinckrodt, Mesoblast, Novoteris, Pharmamar, Revive, Takeda.
The latest global regulatory news, changes and updates affecting biopharma, including: Biotechnology Innovation Organization, Central Drugs Laboratory, Drugs Controller General, EMA, FDA, Gilead Sciences, Health and Human Services, Medicines and Healthcare Products Regulatory Agency, National Institute for Health and Care Excellence, Pfizer Healthcare India, Pharmaceuticals and Medical Devices Agency.
BEIJING – Osaka-based Japanese infectious disease specialist Shionogi & Co. Ltd. said it will partner with Chinese insurance giant Ping An to establish a data-driven joint venture to develop new drugs in a deal involving ¥33.53 billion (US$311 million). It also plans to tap into immuno-oncology to address the patent cliff of its HIV drugs. Under the terms, the Japanese pharma will sell a 2.05% voting stake, or 6.35 million shares of its common stock, to Ping An for ¥33.53 billion. Shionogi will own 51% of the joint venture while Ping An owns 49%, Shionogi IR group manager Kunihiro Mera told BioWorld.
RSS
